GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
HALOZYME THERAPEUTIC (HALO) [hlAlert]

Rating:
Buy HALO
up 89.89 %

HALOZYME THERAPEUTIC (HALO) rated Buy

Posted on: Tuesday,  Jul 24, 2007  9:25 AM ET by Oppenheimer

Oppenheimer rated Buy HALOZYME THERAPEUTIC (NASDAQ: HALO) on 07/24/2007, when the stock price was $9.50. Since
then, HALOZYME THERAPEUTIC has gained 89.89% as of 08/27/2015's recent price of $18.04.
If you would have followed this Oppenheimer's recommendation on HALO, you would have gained 89.89% of your investment in 2956 days.

Halozyme Therapeutics, Inc. (Halozyme) is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix (Matrix) for the endocrinology, oncology, dermatology and drug delivery markets The Company's products are based on the property covering the family of human enzymes known as hyaluronidases. The Company has two marketed products: HYLENEX, a product used as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids, and Cumulase, a product used for in vitro fertilization (IVF). The Company has partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc. (Roche), to apply Enhanze Technology to Roche?s biological therapeutic compounds for up to 13 targets, and with Baxter Healthcare Corporation (Baxter), to apply Enhanze Technology to Baxter?s biological therapeutic compound, GAMMAGARD LIQUID.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/24/2007 9:25 AM Buy
None
9.50 14.00
as of 8/27/2015
1 Week down  -14.58 %
1 Month down  -17.32 %
3 Months up  10.60 %
1 YTD up  20.34 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy